Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street mixed as oil prices surge, investors await earnings, economic data
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
March 18, 2015 4:03 PM EDTJuno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($1.61), $1.28 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
... More


